Literature DB >> 30653341

Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.

Malte P Suppli1, Kristoffer T G Rigbolt2, Sanne S Veidal2, Sara Heebøll3, Peter Lykke Eriksen3, Mia Demant1, Jonatan I Bagger1, Jens Christian Nielsen2, Denise Oró2, Sebastian W Thrane2, Asger Lund1, Charlotte Strandberg4, Merete J Kønig4, Tina Vilsbøll1,5, Niels Vrang2, Karen L Thomsen3, Henning Grønbæk3, Jacob Jelsing2, Henrik H Hansen2, Filip K Knop1,5,6.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) represents a spectrum of conditions ranging from simple steatosis (NAFL), over nonalcoholic steatohepatitis (NASH) with or without fibrosis, to cirrhosis with end-stage disease. The hepatic molecular events underlying the development of NAFLD and transition to NASH are poorly understood. The present study aimed to determine hepatic transcriptome dynamics in patients with NAFL or NASH compared with healthy normal-weight and obese individuals. RNA sequencing and quantitative histomorphometry of liver fat, inflammation and fibrosis were performed on liver biopsies obtained from healthy normal-weight ( n = 14) and obese ( n = 12) individuals, NAFL ( n = 15) and NASH ( n = 16) patients. Normal-weight and obese subjects showed normal liver histology and comparable gene expression profiles. Liver transcriptome signatures were largely overlapping in NAFL and NASH patients, however, clearly separated from healthy normal-weight and obese controls. Most marked pathway perturbations identified in both NAFL and NASH were associated with markers of lipid metabolism, immunomodulation, extracellular matrix remodeling, and cell cycle control. Interestingly, NASH patients with positive Sonic hedgehog hepatocyte staining showed distinct transcriptome and histomorphometric changes compared with NAFL. In conclusion, application of immunohistochemical markers of hepatocyte injury may serve as a more objective tool for distinguishing NASH from NAFL, facilitating improved resolution of hepatic molecular changes associated with progression of NAFLD. NEW & NOTEWORTHY Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in Western countries. NAFLD is associated with the metabolic syndrome and can progress to the more serious form, nonalcoholic steatohepatitis (NASH), and ultimately lead to irreversible liver damage. Using gold standard molecular and histological techniques, this study demonstrates that the currently used diagnostic tools are problematic for differentiating mild NAFLD from NASH and emphasizes the marked need for developing improved histological markers of NAFLD progression.

Entities:  

Keywords:  histomorphometry; nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; transcriptomics

Mesh:

Year:  2019        PMID: 30653341     DOI: 10.1152/ajpgi.00358.2018

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  51 in total

Review 1.  Hepatic sexual dimorphism - implications for non-alcoholic fatty liver disease.

Authors:  Philippe Lefebvre; Bart Staels
Journal:  Nat Rev Endocrinol       Date:  2021-08-20       Impact factor: 43.330

2.  Characterization of regulatory transcriptional mechanisms in hepatocyte lipotoxicity.

Authors:  Joaquín Pérez-Schindler; Elyzabeth Vargas-Fernández; Bettina Karrer-Cardel; Danilo Ritz; Alexander Schmidt; Christoph Handschin
Journal:  Sci Rep       Date:  2022-07-07       Impact factor: 4.996

3.  Adaptation of Oxidative Phosphorylation Machinery Compensates for Hepatic Lipotoxicity in Early Stages of MAFLD.

Authors:  Pia Fahlbusch; Aleksandra Nikolic; Sonja Hartwig; Sylvia Jacob; Ulrike Kettel; Cornelia Köllmer; Hadi Al-Hasani; Stefan Lehr; Dirk Müller-Wieland; Birgit Knebel; Jörg Kotzka
Journal:  Int J Mol Sci       Date:  2022-06-20       Impact factor: 6.208

4.  Aberrant gene expression induced by a high fat diet is linked to H3K9 acetylation in the promoter-proximal region.

Authors:  Núria Morral; Sheng Liu; Abass M Conteh; Xiaona Chu; Yue Wang; X Charlie Dong; Yunlong Liu; Amelia K Linnemann; Jun Wan
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2021-02-06       Impact factor: 4.490

5.  QRICH1 dictates the outcome of ER stress through transcriptional control of proteostasis.

Authors:  Kwontae You; Lingfei Wang; Chih-Hung Chou; Kai Liu; Toru Nakata; Alok Jaiswal; Junmei Yao; Ariel Lefkovith; Abdifatah Omar; Jacqueline G Perrigoue; Jennifer E Towne; Aviv Regev; Daniel B Graham; Ramnik J Xavier
Journal:  Science       Date:  2021-01-01       Impact factor: 47.728

6.  Recapitulating lipid accumulation and related metabolic dysregulation in human liver-derived organoids.

Authors:  Ling Wang; Meng Li; Bingting Yu; Shaojun Shi; Jiaye Liu; Ruyi Zhang; Ibrahim Ayada; Monique M A Verstegen; Luc J W van der Laan; Maikel P Peppelenbosch; Wanlu Cao; Qiuwei Pan
Journal:  J Mol Med (Berl)       Date:  2022-01-20       Impact factor: 4.599

7.  Non-alcoholic fatty liver disease-associated DNA methylation and gene expression alterations in the livers of Collaborative Cross mice fed an obesogenic high-fat and high-sucrose diet.

Authors:  Volodymyr P Tryndyak; Rose A Willett; Mark I Avigan; Arun J Sanyal; Frederick A Beland; Ivan Rusyn; Igor P Pogribny
Journal:  Epigenetics       Date:  2022-03-24       Impact factor: 4.861

8.  Proteasome dysfunction under compromised redox metabolism dictates liver injury in NASH through ASK1/PPARγ binodal complementary modules.

Authors:  Debajyoti Das; Avishek Paul; Abhishake Lahiri; Moumita Adak; Sujay K Maity; Ankita Sarkar; Sandip Paul; Partha Chakrabarti
Journal:  Redox Biol       Date:  2021-06-11       Impact factor: 11.799

9.  USP11 degrades KLF4 via its deubiquitinase activity in liver diseases.

Authors:  Heeyoung Yang; Daeui Park; Jeongho Ryu; Tamina Park
Journal:  J Cell Mol Med       Date:  2021-06-10       Impact factor: 5.310

10.  Hepatic microbiome in healthy lean and obese humans.

Authors:  Malte Palm Suppli; Jonatan Ising Bagger; Benjamin Lelouvier; Amandine Broha; Mia Demant; Merete Juhl Kønig; Charlotte Strandberg; Asger Lund; Tina Vilsbøll; Filip Krag Knop
Journal:  JHEP Rep       Date:  2021-04-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.